Amgen's denosumab shows bone benefit in men
This article was originally published in Scrip
Executive Summary
Amgen's denosumab increases bone mineral density and reduces fracture incidence in men undergoing androgen-deprivation therapy (ADT) for prostate cancer, top-line results from a pivotal Phase III study suggest.